Cognition Therapeutics, Inc.
NASDAQ:CGTXBiotechnology
Healthcare
$0.60 -0.70%
-$0.01 today
- Market cap
- $57.12M
- Beta
- 1.75
- P/E (TTM)
- -6.4
- EPS (TTM)
- -$0.22
52W Low $0.25High $3.83
Volume 0.33M
Average 1.23M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$47.80M
FY 2025 · Annual
Net Income
-$23.49M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 235K | 0 | 0 | 0 |
| Gross Profit | 0 | (235K) | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 18.57M | 30.32M | 37.2M | 41.68M | 37.19M |
| Selling, General & Admin | 10.03M | 13.23M | 13.53M | 12.29M | 10.61M |
| Operating Expenses | 28.6M | 43.32M | 50.72M | 53.97M | 47.8M |
| Depreciation & Amortization | 93K | 235K | 252K | 266K | 228K |
| EBITDA | (10.73M) | (21.13M) | (25.51M) | (33.68M) | (23.25M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (28.6M) | (43.55M) | (50.72M) | (53.97M) | (47.8M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 17.45M | 22.22M | 24.81M | 0 | 0 |
| Interest Expense | 893K | 28K | 27K | 25K | 13K |
| Other Income / Expenses | 16.88M | 22.15M | 24.94M | 20M | 24.31M |
| Income Before Tax | (11.72M) | (21.4M) | (25.79M) | (33.97M) | (23.49M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | (22.15M) | 0 | 0 | 0 |
| Net Income | (11.72M) | 757K | (25.79M) | (33.97M) | (23.49M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.73) | (0.74) | (0.86) | (0.85) | (0.32) |
| EPS (Diluted) | (0.73) | (0.74) | (0.86) | (0.85) | (0.32) |
| 22.23M | 28.99M | 29.99M | 39.73M | 72.77M | |
| 22.23M | 28.99M | 30.03M | 39.73M | 72.77M |
CGTX Earnings Waterfall · TTM
NASDAQ:CGTX · Revenue to Net Income
Key Ratios
EPS$-0.26
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-4.7
P/S Ratio0.0
Analysis
$0 of revenue converted into -$19.6M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-0.26, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 5, 2026 | |
| 10-Q | Quarterly report | Nov 5, 2026 | |
| 8-K | Current report | Oct 22, 2026 | |
| 10-Q | Quarterly report | Aug 7, 2026 | |
| 8-K | Current report | Aug 6, 2026 |
How much revenue does CGTX generate?
Cognition Therapeutics, Inc. (CGTX) reported $0.00 of revenue in fiscal 2025.
Is CGTX profitable?
Cognition Therapeutics, Inc. (CGTX) reported -$23.49M of net income.
Continue the stock analysis
Jump to another research area for this company.